Press Release

Number	Title	Date
12	RegeneRx Announces First Patients Enrolled in Phase 2b/3 U.S. Dry Eye Clinical Trial with RGN-259	2015-09-16
11	GtreeBNT receives approval from FDA for phase 3 clinic trial for GBT-201/RGN-259	2015-08-25
10	GtreeBNT to start phase 3 trial for xerophthalmia medicine	2015-08-05
9	Gtree receives Korean approval to begin phase 2b/3 study of GBT-201 in patients with dry eye syndrome	2015-07-22
8	RegeneRx Korean Licensee Receives Government Approval to Conduct Phase 2b/3 Clinical Trial in Patients with Dry Eye Syndrome	2015-07-17
7	RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S.	2015-04-16
6	GtreeBNT to receive $7.28 million to expand international development of RGN-259/GBT-201	2015-03-09
5	RegeneRx Joint Venture Partner Receives $7.28 million USD From Korean Government and Venture Fund for U.S. Development of RGN-2	2015-03-09
4	RegeneRx and GtreeBNT Create Joint Venture to Develop RGN-259 in the U.S	2015-01-28
3	GtreeBNT files IND with Korean regulatory for phase IIB/III trial of RGN-259 to treat dry eye syndrome	2014-12-31
2	GtreeBNT files IND with MFDS for Phase IIB/III clinical trial of RGN-259 for dry eye syndrome	2014-12-29
1	Entered into a global joint development agreement with RegeneRx	2014-05-15